Camurus AB (publ) (STO:CAMX)
642.00
+2.50 (0.39%)
Oct 13, 2026, 11:37 AM CET
Camurus AB Revenue
Camurus AB had revenue of 702.08M SEK in the quarter ending June 30, 2026, with 3.93% growth. This brings the company's revenue in the last twelve months to 2.27B, up 0.01% year-over-year. In the year 2025, Camurus AB had annual revenue of 2.27B with 21.30% growth. That makes Camurus AB the 16,529th largest company in the world by revenue and 207th in Sweden.
Revenue (ttm)
2.27B
Revenue Growth
+0.01%
P/S Ratio
16.79
Revenue / Employee
7.17M
Employees
316
Market Cap
38.20B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.27B | 397.80M | 21.30% |
| Dec 31, 2024 | 1.87B | 150.73M | 8.78% |
| Dec 31, 2023 | 1.72B | 760.51M | 79.52% |
| Dec 31, 2022 | 956.34M | 355.77M | 59.24% |
| Dec 31, 2021 | 600.57M | 264.57M | 78.74% |
| Dec 31, 2020 | 336.00M | 230.39M | 218.16% |
| Dec 31, 2019 | 105.61M | 56.28M | 114.12% |
| Dec 31, 2018 | 49.32M | -4.99M | -9.18% |
| Dec 31, 2017 | 54.31M | -59.43M | -52.25% |
| Dec 31, 2016 | 113.74M | -41.06M | -26.53% |
| Dec 31, 2015 | 154.80M | -53.41M | -25.65% |
| Dec 31, 2014 | 208.21M | 10.49M | 5.31% |
| Dec 31, 2013 | 197.72M | 102.51M | 107.68% |
| Dec 31, 2012 | 95.20M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioArctic AB | 1.00B |
| Saniona AB | 424.56M |
| Hansa Biopharma AB | 189.46M |
| Genovis AB (publ.) | 135.89M |
| Oncopeptides AB | 95.15M |
| Egetis Therapeutics AB | 66.00M |
| BioInvent International AB | 32.51M |
| Vicore Pharma Holding AB | 3.99M |
Camurus AB News
- 27 days ago - Camurus AB Slides: Company presentation - Filings
- 1 month ago - Camurus AB Slides: Company presentation - Filings
- 2 months ago - Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA - PRNewsWire
- 2 months ago - Camurus AB Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - Camurus AB Quarterly report: Q2 2026 - Filings
- 2 months ago - Camurus AB Slides: Q2 2026 - Filings
- 4 months ago - Camurus' hormone disorder drug expected to be approved in 2027 after fresh FDA setback - Reuters
- 4 months ago - Camurus AB Slides: Company presentation - Filings